Scholarlink

<p>Hearing loss is one of the most prevalent sensory disorders, but no commercial biological treatments are currently available. Here, we identify an East Asia-specific founder mutation, the homozygous c.220 C &gt; T mutation in <i>MPZL2</i>, that contributes to a significant proportion of hereditary deafness cases in our cohort study. We find that the disease-causing mutation can be targetable by adenine base editors (ABEs) that enable A·T-to-G·C base corrections without DNA double-strand breaks. To demonstrate this, we develop a humanized mouse model (<i>hMPZL2</i><sup>Q74X/Q74X</sup>) that recapitulates human <i>MPZL2</i> deafness and leads to progressive hearing loss. A PAM-flexible ABE variant with reduced bystander and off-target effects (ABE8eWQ-SpRY:sgRNA3) is packaged in dual adeno-associated viruses (AAVs) and injected into the inner ear of <i>hMPZL2</i><sup>Q74X/Q74X</sup> mice and effectively corrects the mutation. This treatment significantly restores hearing function, improves inner ear structural integrity, and reverses altered gene expression. Base editing may hold therapeutic potential for hereditary deafness, including most cases of <i>MPZL2</i> deafness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月5日

查看全文
  • Shao Wei Hu,
  • Sohyang Jeong,
  • Luoying Jiang,
  • Hansol Koo,
  • Zijing Wang,
  • Won Hoon Choi,
  • Biyun Zhu,
  • Heeyoung Seok,
  • Yi Zhou,
  • Min Gu Kim,
  • Dan Mu,
  • Huixia Guo,
  • Ziyi Zhou,
  • Sung Ho Jung,
  • Yingting Zhang,
  • Ho Byung Chae,
  • Liheng Chen,
  • Sung-Yeon Lee,
  • Luo Guo,
  • Myung-Whan Suh,
  • Yang Xiao,
  • Moo Kyun Park,
  • Honghai Tang,
  • Jae-Jin Song,
  • Xi Chen,
  • Ai Chen,
  • Jun Ho Lee,
  • Sangsu Bae,
  • Sang-Yeon Lee,
  • Yilai Shu

摘要

Hearing loss is one of the most prevalent sensory disorders, but no commercial biological treatments are currently available. Here, we identify an East Asia-specific founder mutation, the homozygous c.220 C > T mutation in MPZL2, that contributes to a significant proportion of hereditary deafness cases in our cohort study. We find that the disease-causing mutation can be targetable by adenine base editors (ABEs) that enable A·T-to-G·C base corrections without DNA double-strand breaks. To demonstrate this, we develop a humanized mouse model (hMPZL2Q74X/Q74X) that recapitulates human MPZL2 deafness and leads to progressive hearing loss. A PAM-flexible ABE variant with reduced bystander and off-target effects (ABE8eWQ-SpRY:sgRNA3) is packaged in dual adeno-associated viruses (AAVs) and injected into the inner ear of hMPZL2Q74X/Q74X mice and effectively corrects the mutation. This treatment significantly restores hearing function, improves inner ear structural integrity, and reverses altered gene expression. Base editing may hold therapeutic potential for hereditary deafness, including most cases of MPZL2 deafness.